Discordant response comparing 18F-FDG PET/CT with response assessment by RECIST in patients with advanced melanoma treated with immune checkpoint blockade.

Milton Jos De Barros E Silva,Marcos Rezende Teixeira,Natasha Carvalho Pandolfi,Vinícius Fernando Calsavara,Thiago Bueno Oliveira,José Augusto Rinck,Monique Celeste Tavares,Daniel Garcia,Joao Paulo Sn Lima,João Pedreira Duprat

Discordant response comparing 18F-FDG PET/CT with response assessment by RECIST in patients with advanced melanoma treated with immune checkpoint blockade.

2020

Milton Jos De Barros E Silva
Marcos Rezende Teixeira
Natasha Carvalho Pandolfi
Vinícius Fernando Calsavara
Thiago Bueno Oliveira
José Augusto Rinck
Monique Celeste Tavares
Daniel Garcia
Joao Paulo Sn Lima
João Pedreira Duprat

10046Background: Immune checkpoint blockade (ICB) has changed the natural history advanced melanoma (AM). Based on phase III trial, which used RECIST criteria, the complete response (CR) rate with ...

Keywords:

fdg pet ct
Blockade
Oncology
in patient
advanced melanoma
Pathology
response assessment
Medicine
Internal medicine
Immune checkpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations